GILD34:BVMF
Gilead Sciences Inc BDR
R$65.81
0.00%
(0.00) 1D
Okt 16, 4:56:00 PM GMT-3 · BRL
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa GILD34...
Buksan
R$66.36
Mataas
R$66.41
Mababa
R$65.81
Mkt. cap
193.67B
Avg. na dami
261.00
Dami
0.00
Mataas nang 52-wk
R$67.38
Mababa nang 52-wk
R$51.33
Mga natitirang share
1.24B
Bilang ng mga empleyado
17K
Buksan
R$66.36
Mataas
R$66.41
Mababa
R$65.81
Mkt. cap
193.67B
Avg. na dami
261.00
Dami
0.00
Mataas nang 52-wk
R$67.38
Mababa nang 52-wk
R$51.33
Mga natitirang share
1.24B
Bilang ng mga empleyado
17K
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
ad-hoc-news.de
·
2 oras ang nakalipas
Gilead Sciences stock sits 2.32 percent below its yearly high
ad-hoc-news.de
·
3 oras ang nakalipas
Gilead Sciences stock pre-market at EUR 139.78: biotech group slightly higher
The Motley Fool
·
16 oras ang nakalipas
Gilead Sciences Is on an FDA Approval Hot Streak. Should You Buy the Stock Like There's No Tomorrow?
ad-hoc-news.de
·
18 oras ang nakalipas
Gilead Sciences stock trades 0.32 percent above its Xetra close
Profile
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
In 1987, Michael L. Riordan founded the company under the name Oligogen. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its initial public offering in 1992, and successfully developed drugs including Tamiflu and Vistide that decade.
In the 2000s, Gilead began evolving from a biotechnology company into a large pharmaceutical company, through acquisitions and investments, acquiring several subsidiaries. Gilead is a member of the Nasdaq-100 and the S&P 100.
The company has faced criticism over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Tungkol sa Gilead Sciences Inc BDR
CEODaniel O'Day
Mga Empleyado17K
ItinatagHun 22, 1987
HeadquartersFoster City, California, Estados Unidos
Sektor-
Websitegilead.com